Becoming the Leader of Drug Regeneration to Bring First-in-class Therapies for Untreated Serious Diseases

About Us

4P-Pharma is a clinical stage company dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases.

Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, the key differentiation of 4P-Pharma is the dual leverage of in-house R&D capabilities combined with Single Product Vehicle (SPV)-based deployment at clinical stage enabling big pharma clinical collaborations to facilitate market access.

4P-Pharma’s Major Achievements

2014
FOUNDATION
of 4P-Pharma
≥ 300
≥ 300 screened candidates from different source of innovation
≥ 20 candidates evaluated in 4P-Pharma Development’s engine
3 candidates selected for first-in-human
≥ 20
≥ 20 PARTNERSHIPS
with big pharmaceutical companies, innovation sources (biotech companies, SATTs, universities, hospitals, etc.) in France and worldwide
2
2 DISTINCTIONS
- BPI France Excellence
- Seal of Excellence from the European Commission
2
2 SPIN-OFF COMPANIES
2 clinical-stage single product vehicle companies:
- 4Moving Biotech
- 4Living Biotech
2014
FOUNDATION
of 4P-Pharma
≥ 300
≥ 300 screened candidates from different source of innovation
≥ 20 candidates evaluated in 4P-Pharma Development’s engine
3 candidates selected for first-in-human
≥ 20
≥ 20 PARTNERSHIPS
with big pharmaceutical companies, innovation sources (biotech companies, SATTs, universities, hospitals, etc.) in France and worldwide
2
2 DISTINCTIONS
- BPI France Excellence
- Seal of Excellence from the European Commission
2
2 SPIN-OFF COMPANIES
2 clinical-stage single product vehicle companies:
- 4Moving Biotech
- 4Living Biotech
FOUNDATION
of 4P-Pharma

Our Approach : circular pharmaceutical development

4P-Pharma aims to bring to patients’ curative solutions faster by moving away from current linear pharmaceutical development towards circular one :

  • Linking innovative cellular target to disease’s biology
  • Supporting our clinical trials by in silico and data based clinical trials
  • Leveraging on regulatory fast track to target large unmet medical needs

Our Business Model: Translating science to medicines for patients

We aim to evaluate innovative programs with strong scientific rationale, sourced from the top academic research labs and AI based biotechs.

Our R&D capabilities within Pasteur Institute at Lille allow us to assess breakthrough innovations by regenerating active drugs as proprietary first-in-class therapies in the new indication.

Once reaching regulatory milestones, we launch single product vehicles allowing rapid initiation of clinical trials and enabling big pharma collaborations to facilitate access of innovative medicines to patients.

Sourcing our therapeutic candidates

  • Discovery stage candidates with established MoA
  • Open innovation strategy in anchored
    top academic network (Research centers, Hospitals, Universities, Biotechs)

Reaching clinical proof of concept

  • Asset Centric Vehicle incorporation supported by solid preclinical package and proprietary IP portfolio
  • Clinical paths empowered by non captive pharma collaboration
  • Multiple Exit scenario (M&A, clinical stage licensing, commercial-stage cooperation)

Our Daughter Companies

4Living Biotech is dedicated to the clinical development of 4P021, a drug candidate for a curative treatment of acute and chronic pulmonary complications due to viral infection.

4Living Biotech is launching its first international proof of concept phase 2b trial to evaluate the potential of a CXCR4 antagonist to cure severe hospitalized Covid-19 patients.

4Living Biotech entered in a clinical collaboration with Sanofi.

4Moving Biotech is dedicated to the clinical development of 4P004, a disease modifying drug candidate for osteoarthritis showing anti-inflammatory, anti-catabolic and anabolic properties.

4Moving Biotech is launching a phase 1 clinical trial on knee OA patients, to assess intra-articular pharmacokinetic and safety of a GLP-1 analog.

Pipeline

Respiratory infection

4P021

4Living Biotech

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Phase II

Pharmaceutical partner:
Sanofi

Summary:
4P021 is a CXCR4 antagonist for a curative treatment of acute and chronic pulmonary complications due to viral infection.
A first international proof of concept phase 2b trial is launched to evaluate the potential of a CXCR4 antagonist to cure severe hospitalized Covid-19 patients.
4P021 was developed in collaboration with Prof. Patrick Berger‘s team from CHU de Bordeaux, Bordeaux University and INSERM, SATT Aquitaine, and Prof. François Trottein’s team from Institut Pasteur de Lille.
Today, 4P021 is owned by 4P-Pharma’s SPV – 4Living Biotech.

Milestone:
Phase II trial on Covid-19 patients.

Epidemiology:
Influenza virus infections are associated to more than 5 million of hospitalization worldwide per year (Lafond et al. 2021).
In France, in 2021, COVID-19 was associated with a minimum of 859 and up to 6,001 (mean 2,669) daily intensive care bed occupancies. In the United States, it was associated with a minimum of 3,525 and a maximum of 28,891 (mean 13,978) daily critical care bed occupancies (Our World in Data website).

Osteoarthritis

4P004

4Moving Biotech

  • Drug discovery
  •  
  • Preclinical
  •  
  • Phase I
  •  
  • Phase II
Phase I

Pharmaceutical partner:
Partnering opportunity

Summary:
4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties.

4P004 was developed in collaboration with the team of Prof. Francis Berenbaum (St-Antoine’s hospital in Paris, APHP and Sorbonne University) and SATT Lutech.

Today, 4P004 is owned by 4P-Pharma’s SPV – 4Moving Biotech.

Milestone:
Phase I trial on OA patients

Market:
≥ 300 Millions of people have OA in the world (Kloppenburg et al., 2020)

Estimated sales per year : 3-4 Milliards/year (GlobalData: https://www.globaldata.com/osteoarthritis-7mm-market-set-to-be-worth-3-5-billion-by-2026/)

Our Team

Our team, our key driver for our success

4P-Pharma is a passionate and complementary team of drug developers, combining scientific, clinical, pharmaceutical, financial, and business experts, and sharing the same vision: bring curative therapies to people with serious diseases. 

Our young, human-sized team of 15 employees is always happy to welcome new talents. Each of our employees is amazing, but it is together that we make 4P-Pharma such a dynamic, proactive and creative company.

Our Partners

News

4Living Biotech obtains clinical trial authorizations in Europe to iniatiate LEONARDO trial

4Living Biotech, a biotechnology company and 4P-Pharma’s daughter company, specializing in the treatment of respiratory infections obtained ANSM and two other European agencies approvals to initiate the LEONARDO phase IIb clinical study in patients with acute and chronic complications of COVID-19 LEONARDO trial leverages on recent studies showing that the expression of CXCR4 receptor in&hellip

Read More

4 questions au professeur Guillaume Canaud

 En tant que scientifique, associez-vous un ou des objectifs spécifiques à votre activité de recherche ? Si oui lequel ou lesquels ? Pr. Canaud: Oui effectivement, je me pose, ou plutôt nous nous posons car il s’agit d’un travail d’équipe, deux questions clés :  1-Comment cela fonctionne-t-il ?  2-Comment utiliser nos connaissances pour améliorer la vie des&hellip

Read More

4P-PHARMA IN “SMART MORNING SOUMIER”

Revital Rattenbach, 4P-Pharma’s chairwoman has been interviewed by Stéphane Soumier in “Smart Morning Soumier”. The program is broadcasted on June 30th, 2022, on B SMART TV and RTL. ​ For more information: click here

Read More
Contact us

Send us an e-mail

Lille
Campus de l’Institut Pasteur de Lille
1 Rue du Professeur Calmette
59000 Lille, France
Locate on Maps
Paris
74 rue du Faubourg Saint-Antoine
75012 Paris, France
Locate on Maps